Saccharomyces fungemia associated with esophageal disease identified by D1/D2 Ribosomal RNA gene sequence  by Cheema, A. et al.
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urvey. 38% of cases of candidaemia were caused by C. albi-
ans and 62% by non-albicans strains.
Methods: 92 episodes in 92 patients with fungaemia and
vailable clinical data were analysed according to data from
RFs. Informations about risk factors, antifungal treatment
nd outcome 4 weeks after the onset of infection were col-
ected.
Results: All patients except 16.3% were adults >18 years
ld. Majority of patients were hospitalized on ICU (59.7%);
3.4% of patients had cancer and 16.3% had haematological
alignancy. 20% of patients were neutropenic at the onset
f candidaemia. Previous antibacterial treatment (93.4%),
nserted central venous catheter (83.6%), total parenteral
utrition (55.4%), surgical procedure (52%) and colonisation
ith Candida spp. were the most common risk factors asso-
iated with candidaemia. Fluconazole was the preferred
st line drug (58.6% of all treated patients) followed by
oriconazole (18.4%) and Amphotericin B (10.8%). 6 patients
6.5%) did not receive any antifungal therapy - 2/6 died and
/6 survived.
Fungaemia-related and candidaemia-related mortality
as 33.7% and 27.2%, respectively. 16/25 (64%) deaths were
ue to candidaemia caused by non-albicans candida strains
nd 9/25 (36%) were associated with C.albicans.
Conclusion: Mortality of patients with candidaemia
eﬂects the epidemiological trend in Slovakia where major-
ty of cases are caused by non-albicans strains. The choice of
ntifungal therapy should be in concordance with epidemi-
logical data.
oi:10.1016/j.ijid.2010.02.1763
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le of isolates in a teaching hospital from São Paulo-Brazil
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norio5, F. Rossi 6
Hospital das Clinicas da Faculdade de Medicina da Univer-
idade de São Paulo, São Paulo, Brazil
Hospital das Clínicas da Faculdade de Medicina da Univer-
idade de São Paulo, São Paulo, Brazil
Hospital das Clínicas da Faculdade de Medicina da Univer-
idade de São Paulo, São Paulo, São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina da Univer-
idade de São Paulo, Sao Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina da Univer-
idade de Sao Paulo, SP, Brazil
Hospital das Clínicas da Faculdade de Medicina da Univer-
idade de São Paulo, São Paulo, NA, Brazil
Background: To describe the percentage of Cryptococ-
us neoformans and Cryptococcus gattii encountered in our
ospital, a 2500-bed teaching hospital of São Paulo, and
o compare minimal inhibitory concentrations to different
ntifungal drugs.
Methods: Consecutive and no duplicate clinical isolates
ecovered from patients with infections (meningitis, cryp-
ococcaemia, pneumonia and peritonitis) between 2006 and
008 were included for analysis. Identiﬁcation to the species
evel was performed by conventional methods based on
rowth appearance on Sabouraud dextrose agar at 37 ◦C,
A
t
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roduction of urease and the presence of a capsule. Results
ere conﬁrmed using the API 20C (bioMerieux, St Louis,
SA). L-canavanine-glycine-bromothymol blue agar (CGB)
as used to distinguish C. gattii from C. neoformans. Min-
mal inhibitory concentrations (MIC) to amphotericin B,
aspofungin, 5-ﬂuorocytosine, posaconazole, ﬂuconazole,
traconazole and voriconazole were determined using Sen-
ititre Yeast-One Y8TM (TREK Diagnostic Systems, Cleveland,
SA).
Results: In the study period 43 isolates were included.
hirty three (77%) were C. neoformans and 10 (23%) were
. gatti. C. neoformans MIC 50/90 for antifungal drugs were
s follow: amphotericin B.(0.5mg/L -1mg/L,) caspofungin
16mg/L-16mg/L), posaconazol (0.064mg/L-0.25mg/L),
uconazole, (4mg/L-16mg/L); itraconazol (0.125mg/L-
.5mg/L) and voriconazol (0.032mg/L-0.125mg/L) C.
atti MIC 50/90mg/L for antifungal drugs were as
ollow: amphotericin: (0.5 -1mg/L); caspofungin (16mg/L-
2mg/L); posaconazole (0.125mg/L-0.25mg/l); ﬂucona-
ole: (8mg/L-16mg/L); itraconazole (0.25mg/L-0.5mg/L)
nd for voriconazole (0.125mg/L-0.25 mg/L). Fluconazole
ICs equal or higher than 16mg/L was observed among 40%
f C. gattii and only 18% among C. neoformans isolates.
Conclusion: Species identiﬁcation among Cryptococcus
pp isolates is an important epidemiological tool and should
e done in a routine basis. C gattii showed higher ﬂucona-
ole MICs and it should be closed monitored.
oi:10.1016/j.ijid.2010.02.1764
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accharomyces fungemia associated with esophageal dis-
ase identiﬁed by D1/D2 Ribosomal RNA gene sequence
. Cheema1,∗, J. Farrell 2, C. Kurtzman3
University of Illinois College of Medicine at Peoria, Peoria,
L, USA
OSF St. Francis, Peoria, IL, USA
National Center for Agricultural Utilization Research, ARS,
SDA, Peoria, IL, USA
Background: We describe two immunocompromised
atients with ultimately fatal esophageal pathology and Sac-
haromyces cerevisiae fungemia. Originally misidentiﬁed by
itek automated techniques, both yeast were ultimately
dentiﬁed by D1/D2 LSU rRNA gene sequence. Neither
atient had received probiotics.
Methods: Case 1: A 49-year-old intoxicated homeless
ale with a history of chronic alcoholism was admitted
or workup of hypoxia. Patient described a chronic cough
nd a 60 pound weight loss over six months. Examination
as notable for cachexia, poor dentition, and inspiratory
tidor. CT scan revealed a neck mass compromising the
atient’s airway. A PET scan demonstrated a hyperme-
abolic mass in the mediastinum with paratracheal lymph
ode uptake consistent with metastatic malignant disease.
ygosaccharomyces bailii was identiﬁed in blood cultures
rom admission and on hospital day three. Intravenous
mphotericin B treatment was initiated. Subsequent cul-
ures were negative.
Results: Case 2: An 87-year-old woman with hiatal hernia
as admitted with gastrointestinal obstruction. Examination
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high mortality. In Colombia, a high proportion of patients
never received antifungal therapy even with laboratory
proven infection.
doi:10.1016/j.ijid.2010.02.176714th International Congress on Infectious Diseases (ICID) Abs
was remarkable for hypotension and tachycardia (no oral
thrush). Esophagogastroduodenoscopy revealed fecal mat-
ter in the esophagus and stomach. Post volvulus repair, the
patient developed sepsis, secondary to an esophageal perfo-
ration. Surgical closure was performed and she was treated
with broad spectrum antibiotics and corticosteroids. Blood
cultures were positive for Candida albicans (two occasions)
and Saccharomyces cerevisiae (one occasion) fungemia. Flu-
conazole was added to the antibiotic treatment. Patient
never fully recovered and care was withdrawn.
Conclusion: Disseminated Saccharomyces infection has
been reported in immunosuppressed patients treated with
probiotics, but disseminated Saccharomyces cerevisiae
infection associated with underlying esophageal disease is
not previously described. Saccharomyces cerevisiae (which
occasionally colonizes the gastrointestinal tract) is closely
related to Candida albicans, and may be misidentiﬁed by
common automated microbiologic systems. The relative
resistance of Saccharomyces cerevisiae to azole drugs and
its ability to cause widespread infections with multi-organ
involvement makes rapid, correct identiﬁcation critical.
Using the standard yeast card, the Vitex-2 system iden-
tiﬁed one yeast as Saccharomyces cerevisiae and one
as Zygosaccharomyces bailii. We found no documented
cases of Zygosaccharomyces fungemia so we employed DNA
sequencing to conﬁrm the Vitek identiﬁcation. Based on the
nucleotide sequence of the D1/D2 LSU ribosomal RNA gene
both the fungi were identiﬁed as Saccharomyces cerevisiae.
doi:10.1016/j.ijid.2010.02.1765
30.025
Determination of antifungal susceptibility in immunocom-
promised patients
L. Siegfried ∗, V. Hrabovsky, M. Sabol
University P.J.Safarik, Faculty of Medicine, Kosice, Slovakia
Background: The aim of the study was to compare anti-
fungal sensitivity of yeasts to selected antimycotics isolated
from immunocompromised patients with hematooncological
disorders and critically diseased patients in intensive care
units with sensitivity of yeasts isolated from immunocompe-
tent individuals.
Methods: Within the period between August 2007 and
October 2008, we examined 450 samples of clinical mate-
rial isolated from hospitalized patients with both proven
and suspected mycotic infection. Yeasts isolates were iden-
tiﬁed by Chromagar Candida and AUXACOLOR 2 biochemical
test. Susceptibility to antimycotic agents such as ﬂuconazole
(FLZ), ketoconazole (KTZ), itraconazole (ITZ), voricona-
zole (VRZ), ﬂucotysine (5FC), amphotericin B (AMB), and
caspofungin (CAF) was determined by microdilution method
according to CLSI M27-A2 standard procedure.
Results: Among all isolates nine yeast species were iden-
tiﬁed, the most frequently C. albicans strains (n = 151),
followed by C. glabrata (n = 21), C. krusei (n = 11), S. cere-
visiae (n = 8), C. parapsilosis (n = 7), C. tropicalis (n = 3), C.
guiliermondii (n = 3), C. kefyr (n = 2) and C. lusitaniae (n = 2).
Among yeasts isolated from immunocompromised patients
the incidence of non-albicans Candida was 42.6% while
only 17% among yeasts isolated from immunocompetentts e127
atients. Incidence of resistance of commonly susceptible
pecies to the tested antimycotics was rare. The resis-
ance to 5-FC (MIC≥ 32g/mL) was showed only in case
f two C. albicans strains. The highest resistance, specif-
cally to azole antimycotics, was observed in C. glabrata
trains, amongst which, except VRZ (MIC≥ 32g/mL), resis-
ant strains to FLZ (MIC≥ 64g/mL), KTZ (MIC > .125g/mL)
nd ITZ (MIC≥ 1g/mL) were found.
Conclusion: Results obtained in the study showed a higher
ncidence of non-albicans Candida yeasts in immunocompro-
ised patients. We did not ﬁnd signiﬁcant differences in
usceptibility of yeasts isolated from immunocompromised
nd immunocompetent patients.
oi:10.1016/j.ijid.2010.02.1766
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andidemia in third level hospitals in Bogotá, Colombia
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Colombia
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Background: Candidemia is a serious infectious compli-
ation among critical and immunosupressed patients.
Methods: Patients with laboratory conﬁrmed candidemia
ere prospectively followed. Candida isolates were sent to
reference laboratoryfor identiﬁcation and susceptibility.
isk factors and clinical data were taken from the medical
ecord. Antifungal use and ﬁnal outcome were registered.
Results: 131 episodes were followed, 61% women, with
ges between 9 days and 87 years. 50% of blood cultures
ere positive after 34 hours (in 44% of the patients blood
ultures were posiitve in more than one bottle). More fre-
uently found risk factors for candidemia were stay in ICU
8%), previous antibiotic use (77%), parenteral nutrition
54%), previous abdominal surgery (40%), previous use of
mmunosuppresors (29%). Candida species identiﬁes were C.
lbicans (67%), followed by C. parapsilosis (14%) and C. trop-
calis (10%). Susceptibility to ﬂuconazole were high among
. albicans and C. tropicalis isolates, but not for the other
onalbicans isolates. Fluconazole was the preferred drug of
hoice (57%), followed by amphotericin deoxycholate (18%).
8% of the patients never received antifungal therapy. Mor-
ality was high after two weeks of treatment (20%) and was
ven higher at discharge (36%).
Conclusion: Candidemia is a severe complication with
